Trials / Unknown
UnknownNCT04623333
A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
A Single-arm, Open-label, Multicenter, Phase II Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2020-11-30
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
- First posted
- 2020-11-10
- Last updated
- 2020-11-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04623333. Inclusion in this directory is not an endorsement.